U.S. Food and Drug Administration (FDA) Actions in 2026
Major actions the U.S. Food and Drug Administration has taken in 2026 on foods and food chemicals, dietary supplements, compounded drugs, plant medicines and psychedelics, and drug labels. Each page reports the action from the primary documents — the U.S. Food and Drug Administration (FDA) announcement, the Federal Register notice, the order or letter itself — with what it did, what it did not do, and where it stands as of October 2026.
U.S. Food and Drug Administration Actions in 2026 (12)
In date order, oldest first. The stars rate each action's legal weight: ★★★★★ a final action that changes what is sold or labelled nationwide; ★★★★ a proposed rule or order, or a final action of narrower reach; ★★★ a formal safety review or a final guidance; ★★ a request for information or a public meeting.
U.S. Food and Drug Administration Food Dye Actions in 2026
2026: the U.S. Food and Drug Administration revoked Orange B, proposed revoking Citrus Red No. 2, approved beetroot red and widened spirulina extract, and relaxed “no artificial colors” claims.
Read the full action →U.S. Food and Drug Administration Safety Reassessments of BHA, BHT and ADA (2026)
2026: the U.S. Food and Drug Administration opened post-market safety reassessments of the preservatives BHA and BHT and the dough conditioner azodicarbonamide, and finalized its chemical-review framework.
Read the full action →U.S. Food and Drug Administration Approves New Menopausal Hormone Therapy Labels (2026)
February 2026: the U.S. Food and Drug Administration approved the first six hormone therapy labels without boxed-warning statements on heart disease, breast cancer and probable dementia.
Read the full action →U.S. Food and Drug Administration Public Meeting on What Counts as a Dietary Ingredient (2026)
March 2026: the U.S. Food and Drug Administration asked for public input on how the “dietary substance” category applies to fermentation-made, cell-cultured and recombinant supplement ingredients.
Read the full action →U.S. Food and Drug Administration Review of Compounded Peptides Including BPC-157 (2026)
2026: BPC-157 and other peptides left the U.S. Food and Drug Administration’s significant-safety-risk category; in July the U.S. Food and Drug Administration proposed not listing any of the seven it took to its advisory committee.
Read the full action →U.S. Food and Drug Administration Proposal on Compounded Semaglutide and Tirzepatide (2026)
April 2026: the U.S. Food and Drug Administration proposed keeping semaglutide, tirzepatide and liraglutide off the list outsourcing facilities may compound from bulk ingredients, finding no clinical need.
Read the full action →7-OH Kratom Products: The 2026 Scheduling Steps
July 2026: the DEA moved to place concentrated 7-OH in Schedule I, with U.S. Department of Health and Human Services (HHS) and U.S. Food and Drug Administration support; natural kratom leaf is not the target.
Read the full action →U.S. Food and Drug Administration Final Guidance on Psychedelic Drug Trials (2026)
July 2026: the U.S. Food and Drug Administration finalized its guidance on designing clinical trials of psychedelic drugs and held a public hearing on possible future therapeutic use.
Read the full action →U.S. Food and Drug Administration Proposal to Make Generally Recognized as Safe Notices Mandatory (2026)
August 2026: the U.S. Food and Drug Administration proposes requiring companies to notify it whenever they conclude a food ingredient is generally recognized as safe (GRAS); comments close December 9, 2026.
Read the full action →U.S. Food and Drug Administration Request for Input on Botanical Drugs (2026)
September 2026: the U.S. Food and Drug Administration asked for public input on obstacles to developing plant-based prescription drugs, from quality standards to study design; comments close November 3.
Read the full action →U.S. Food and Drug Administration Ibogaine Research Notice (2026)
October 2026: the U.S. Food and Drug Administration asks for public comment on how early clinical trials of ibogaine should be designed (comments through November 20, 2026).
Read the full action →U.S. Food and Drug Administration Final Rule on Salt Substitutes in Standardized Foods (2026)
October 2026: a final rule lets 139 standardized foods, from bread to cheddar cheese, replace some or all added salt with safe and suitable salt substitutes; effective December 14, 2026.
Read the full action →Connections
- U.S. Food and Drug Administration Actions in 2021
- U.S. Food and Drug Administration Actions in 2022
- U.S. Food and Drug Administration and Regulation
- U.S. Food and Drug Administration Actions in 2025
- U.S. Food and Drug Administration Actions in 2024
- U.S. Food and Drug Administration Actions in 2023
- Ibogaine: History, Pharmacology and Safety
- News: Six Findings, October 11, 2026
- News
- Medicines and Oils
- Remedies
- Toxins
- Pharmacology